RxDoctor Payments Data

Nancy Naghavi, DO

Family Medicine · Katy, TXNPI 1811978901

Payments from drug & device makers

$1,854in general payments, 2019–2025

Across 114 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$701
  • Lilly USA, LLC$376
  • Boehringer Ingelheim$236
  • Exact Sciences$97
  • Hologic Sales And Service, LLC$95
  • Astellas Pharma US Inc$62
  • plus $286 from 9 others

What the payments were for

  • Food & beverage$1,84299%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,854 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$89,396
Medicare patients
204
Services billed
1,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide74$110,676
JardianceEmpagliflozin59$68,483
FarxigaDapagliflozin Propanediol52$66,677
TrulicityDulaglutide48$63,228
EliquisApixaban43$52,873
OzempicSemaglutide28$26,897
LinzessLinaclotide12$19,284
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$11,928
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$3,859
Levothyroxine Sodium204$2,248
SynthroidLevothyroxine Sodium37$2,087
Atorvastatin Calcium254$1,969
Omeprazole110$1,768
Olmesartan Medoxomil62$1,761
Ezetimibe56$1,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$376$173,904122 claims
AstraZenecaFarxiga, Breztri Aerosphere$701$78,60565 claims
Boehringer IngelheimJardiance$236$68,48359 claims
PfizerEliquis$37$52,87343 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Katy

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →